CXCL8 and prostate carcinoma: On the other hand, VK2 inhibited the expression of IL-6 in 22RV1 and DU-145 cells in addition to downregulating HMGB1, RAGE, IL-8, and VEGF-A in these advanced prostate cancer cells (Figures 7(d)–7(i)).